First-in-Human Granzyme B PET Tracer Tested to Predict Checkpoint Inhibitor Response
A small phase 1 trial tested the safety of a PET tracer that images granzyme B, a marker of immune cell killing, in cancer patients on checkpoint inhibitors.
Summary
Checkpoint inhibitors help many people with cancer, but doctors cannot easily tell early on who will respond. This early-stage trial tested a new imaging agent, a radioactive tracer called [68Ga]-NOTA-hGZP, designed to bind granzyme B. Granzyme B is a protein that immune killer cells release to destroy tumor cells. In theory, a PET scan using the tracer could show whether the immune system is actively attacking a tumor. The study enrolled 13 adults with solid tumors or lymphoma who were receiving a checkpoint inhibitor, either alone or combined with other immunotherapy. It was a single-arm phase 1 study focused mainly on first-in-human safety. The trial is listed as completed, but the available record includes no results, so we do not yet know how safe the tracer was or whether it predicts treatment response. It is an early step toward a tool for guiding immunotherapy decisions.
Detailed Summary
Why this matters: Immune checkpoint inhibitors have changed cancer care, yet only a portion of patients benefit, and some face significant side effects. Clinicians lack reliable, noninvasive ways to learn early whether the immune system is engaging a tumor. A dependable early signal could spare patients ineffective treatment and guide switching to other options.
What was studied: This phase 1 trial, sponsored by Cytosite Biopharma, evaluated [68Ga]-NOTA-hGZP, a PET imaging agent that targets granzyme B. Granzyme B is a protease released by activated cytotoxic T cells and natural killer cells to induce death of target cells. Imaging it could provide a direct readout of active immune killing within tumors.
Design and population: The study was a single-arm, first-in-human safety trial. Thirteen adults with unspecified solid tumors or lymphoma were enrolled. All were undergoing treatment with a checkpoint inhibitor, either as monotherapy or in combination immuno-oncology regimens. The trial began in June 2020, and its status is listed as completed, with a completion date of June 2025.
Key results: The registry entry supplies no results. There are no data on adverse events, tracer distribution, image quality, or any relationship between tracer uptake and tumor response or survival. The stated primary purpose was safety, so the hypothesis that granzyme B imaging predicts response remains untested in this record.
Implications: If later studies confirm safety and show that tracer uptake tracks with clinical benefit, granzyme B PET could become a tool for early response assessment and for evaluating new immunotherapy combinations. It also illustrates a broader push toward functional imaging of immune activity rather than relying only on tumor size changes.
Caveats: This summary is based on the registry abstract only, with no published results. The sample is very small and heterogeneous, there is no control group, and predictive value cannot be judged. Findings from larger, tumor-specific trials will be needed.
Key Findings
- Phase 1 trial tested [68Ga]-NOTA-hGZP, a PET tracer targeting granzyme B, in 13 adults on checkpoint inhibitors.
- Granzyme B reflects active killing by cytotoxic T cells, offering a possible direct readout of immune attack.
- Primary aim was first-in-human safety; the record reports no safety or imaging results.
- Participants had solid tumors or lymphoma, treated with checkpoint inhibitors alone or combined with immunotherapy.
Methodology
Single-arm, open phase 1 first-in-human study enrolling 13 adults with solid tumors or lymphoma receiving checkpoint inhibitor therapy. Sponsored by Cytosite Biopharma, it ran from June 2020 and is listed as completed in June 2025. The record specifies safety as the focus.
Study Limitations
This summary is based on the registry abstract only, which reports no results. The sample of 13 is small and mixed across tumor types, with no comparator, so neither safety nor predictive value can be assessed here.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
